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Introduction {#sec1}
============

Somatic cells can be reprogrammed to a pluripotent state (induced pluripotent stem \[iPS\] cells) by defined transcription factors (*Oct3/4*, *Sox2*, *Klf4*, and c-*Myc*, hereafter referred to as OSKM) ([@bib24]). iPS cells are almost equivalent to embryonic stem cells (ESCs) in their properties ([@bib13], [@bib10]). Many studies have been done to elucidate the mechanism of reprogramming ([@bib23], [@bib18], [@bib2]), and several factors that affect reprogramming efficiency have also been revealed ([@bib7], [@bib14], [@bib3]). But the importance of cell-cell interactions and secreted, extracellular molecules in reprogramming has not been extensively studied.

To approach this problem, we focused on EPHRIN receptor (EPH)/EPHRIN (EFN) signaling pathways. EPH receptors and EPHRINs are both anchored to the plasma membrane and form an important cell communication system with roles in normal physiology and disease pathogenesis ([@bib17]). The EPH/EPHRIN signals propagate bidirectionally into both the EPH-expressing cells (forward signaling) and the EPHRIN-expressing cells (reverse signaling) to elicit different effects on each cell ([@bib16]). Several EPH receptors and EPHRINs have truncated forms, which are secreted and function to propagate or repress signals ([@bib1], [@bib4], [@bib25]). Recently, some of EPH receptors and EPHRINs have been identified as regulators of stem and progenitor cell proliferation ([@bib5], [@bib6], [@bib8], [@bib12]). However, whether EPH/EPHRIN signaling pathways regulate cell reprogramming has been unknown.

In this study, we found that EPHA7, among EPH and EFN members, is most prominently upregulated during reprogramming and that secreted, truncated EPHA7 plays a crucial role in reprogramming through inducing ERK activity reduction.

Results {#sec2}
=======

EPHA7 Is Prominently Upregulated during Mouse Embryonic Fibroblast Reprogramming {#sec2.1}
--------------------------------------------------------------------------------

We measured the changes in the expression levels of *Eph*- and *Efn*-family genes during OSKM-induced reprogramming of mouse embryonic fibroblasts (MEFs) and found that *EphA7* shows the most prominent upregulation. The upregulation of *EphA7* preceded the induction of *E-cadherin* and the pluripotency markers *Nanog* and *Oct3/4* ([Figures 1](#fig1){ref-type="fig"}A, 1B, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). Because there exists a secreted, truncated form of EPHA7 (truncated EPHA7), which is a splice variant and lacks kinase activity ([@bib4], [@bib15]), we examined truncated *EphA7*. Truncated *EphA7* was markedly upregulated from early periods of reprogramming ([Figure 1](#fig1){ref-type="fig"}A). But the expression levels of *EphA7* and truncated *EphA7* were low in established iPS cells and ESCs ([Figure 1](#fig1){ref-type="fig"}A).

The protein level of full-length EPHA7 was increased markedly at day 4 and then gradually decreased, and truncated EPHA7 protein was markedly increased at day 6 ([Figure 1](#fig1){ref-type="fig"}C). Analyses of the conditioned medium indicated that truncated EPHA7 protein was secreted during reprogramming ([Figures 1](#fig1){ref-type="fig"}D and 1E).

We next examined which factor is responsible for the upregulation of *EphA7*. Ectopic expression of *Oct3/4* alone, but not *Sox2*, *Klf4*, or c-*Myc*, in MEFs resulted in marked increases in the expression levels of both full-length *EphA7* and truncated *EphA7* ([Figure 1](#fig1){ref-type="fig"}F), indicating that OCT3/4 plays a major role in the induction of *EphA7*. The analysis showed that OCT3/4 strongly upregulated the expression of both full-length and truncated *EphA7* within 24 hr ([Figure 1](#fig1){ref-type="fig"}G). Chromatin immunoprecipitation assays showed that OCT3/4 directly bound to at least one site among five potential OCT3/4-binding sites ([Figure 1](#fig1){ref-type="fig"}H) ([@bib11]) in the upstream region of *EphA7* ([Figure 1](#fig1){ref-type="fig"}I), suggesting that OCT3/4 directly regulates the expression of *EphA7*. OCT3/4 weakly bound to the *EphA7* promoter region in ESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}C), consistent with the low expression of *EphA7* in ESCs.

Truncated EPHA7 Plays a Crucial Role in Reprogramming {#sec2.2}
-----------------------------------------------------

We then examined the effect of *EphA7* knockdown on the reprogramming efficiency. *EphA7* mRNA levels were markedly reduced by each *EphA7* small hairpin RNA (shRNA) ([Figure 2](#fig2){ref-type="fig"}A). The protein levels of both full-length and truncated EPHA7 and the amounts of secreted, truncated EPHA7 protein were markedly reduced by each *EphA7* shRNA ([Figure S2](#mmc1){ref-type="supplementary-material"}A). *EphA7* knockdown resulted in marked reduction in the mRNA and protein levels of NANOG ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A) and the numbers of alkaline phosphatase--positive colonies and NANOG-positive colonies ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}B). The efficiency of OSK-mediated reprogramming was also markedly reduced by *EphA7* knockdown ([Figure S2](#mmc1){ref-type="supplementary-material"}C). These results show that EPHA7 promotes reprogramming.

We examined whether introduction of EPHA7 could reverse the decreased reprogramming efficiency of *EphA7*-knockdown cells. When full-length EPHA7 was introduced to *EphA7*-knockdown cells, the reprogramming efficiency was not improved ([Figures 2](#fig2){ref-type="fig"}D, 2F, and [S2](#mmc1){ref-type="supplementary-material"}D). In contrast, the addition of EPHA7^FC^, which is a truncated form of EPHA7 protein, to the culture medium markedly increased reprogramming efficiency ([Figures 2](#fig2){ref-type="fig"}E, 2F, [S2](#mmc1){ref-type="supplementary-material"}E, and S2F). These results indicate that secreted, truncated EPHA7, but not full-length EPHA7, contributes to promoting cell reprogramming. The addition of EPHA7^FC^ enhanced the reprogramming efficiency of control MEFs ([Figures 2](#fig2){ref-type="fig"}E and 2F). We then examined whether truncated EPHA7 acts on specific phases of reprogramming or all the way along reprogramming. Data showed that the number of NANOG-positive colonies was significantly increased when EPHA7^FC^ was added after day 6 ([Figure 2](#fig2){ref-type="fig"}G), suggesting that truncated EPHA7 has a stronger effect on the middle and/or late phases than on the early phase.

Knockdown of *EfnA3*, which shows the most prominent upregulation during reprogramming among *Ephrin* genes, did not significantly affect reprogramming efficiency ([Figure S2](#mmc1){ref-type="supplementary-material"}G). This result, together with the above finding that truncated EPHA7, which is shown to function to inhibit EPH signaling ([@bib4], [@bib15]), but not full-length EPHA7, plays a positive role in reprogramming, suggests that inhibition of EPH signaling is important for reprogramming. Because there are many other ligands for EPHA7, knockdown of *EfnA3* may not produce a large effect.

Truncated EPHA7 Promotes Cell Reprogramming by Inducing ERK Activity Reduction {#sec2.3}
------------------------------------------------------------------------------

It has previously been shown that secreted, truncated EPHA7 inhibits EPH signaling, which induces the phosphorylation and activation of ERK1/2 in lymphomas ([@bib15]), and that the levels of phosphorylated ERK1/2 (pERK1/2) are increased when mouse ESCs lose pluripotency and start to differentiate ([@bib9]). We thus reasoned that truncated EPHA7 would regulate cellular reprogramming by controlling ERK1/2 activity. We then examined pERK1/2 levels during reprogramming and found that pERK1/2 levels were markedly reduced after day 6 of reprogramming in parallel with EPHA7 upregulation ([Figure 3](#fig3){ref-type="fig"}A, OSKM; [Figures 1](#fig1){ref-type="fig"}A--1E).

The analysis revealed that the reduction of pERK1/2 levels during reprogramming was suppressed in *EphA7*-knockdown cells ([Figure 3](#fig3){ref-type="fig"}B). pERK1/2 levels were reduced to the lowest level at day 6, when the induction of E-CADHERIN began to occur ([Figure 3](#fig3){ref-type="fig"}B). Remarkably, the addition of EPHA7^FC^ to the culture medium reversed the *EphA7* knockdown-induced suppression of pERK1/2 reduction and thus caused pERK1/2 reduction again ([Figure 3](#fig3){ref-type="fig"}C).

Because ERK1/2 activity reduction is likely to play a role in promoting cellular reprogramming, we examined whether treatment with the specific inhibitor of MEK, an activator of ERK1/2, gives the same effect as the addition of truncated EPHA7 on reprogramming. The results showed that incubation of *EphA7*-knockdown cells with the MEK inhibitor PD0325901 during the reprogramming process significantly restored reprogramming efficiency ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}A). Moreover, PD0325901 treatment enhanced the reprogramming efficiency of control MEFs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These effects were the same as those of the addition of truncated EPHA7 (see [Figure 2](#fig2){ref-type="fig"}E). Furthermore, EPHA7^FC^ and MEK inhibition did not have additive effects on reprogramming efficiency ([Figure 3](#fig3){ref-type="fig"}E). These results support our idea that truncated EPHA7 promotes cellular reprogramming by inducing ERK1/2 activity reduction.

Inhibition of MEK is shown to be helpful to ESC establishment and maintenance ([@bib26], [@bib19], [@bib21]). To examine whether truncated EPHA7 has an effect on pluripotency maintenance, ESCs were treated with EPHA7^FC^, and mRNA levels of pluripotency markers, such as *Nanog* and *Klf2*, were examined. Data showed that EPHA7^FC^ did not increase the expression of pluripotency marker genes, while treatment with PD0325901 or 2i (PD0325901 and CHIR99021; GSK-3β inhibitor) significantly increased their expression ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Furthermore, EPHA7^FC^ treatment did not reduce pERK1/2 levels in ESCs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Thus, the regulation of ERK1/2 activity by truncated EPHA7 may not be involved in pluripotency maintenance in ESCs.

Pre-reprogrammed Cells Secrete Truncated EPHA7 and Support SSEA-1 Negative Cells to Progress toward a Pluripotent State {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------

We examined pERK1/2 levels of cells, which were sorted by the expression intensity of SSEA-1, an early pluripotency marker, or that of NANOG ([Figure S4](#mmc1){ref-type="supplementary-material"}A). The analysis revealed that pERK1/2 levels were reduced to a greater extent in SSEA-1- and NANOG-positive cells than in SSEA-1- and Nanog-negative cells, respectively ([Figure 4](#fig4){ref-type="fig"}A), suggesting that the progress of reprogramming is accompanied by the reduction of pERK1/2 levels.

We then found that both full-length *EphA7* and truncated *EphA7* were expressed to a much higher extent in NANOG-negative cells than in NANOG-positive cells at the late time point (day 12) of reprogramming ([Figure 4](#fig4){ref-type="fig"}B). Moreover, we performed puromycin selection experiments by using MEFs derived from *Nanog*-GFP-IRES-PuroR mice ([@bib13]), which express GFP and the puromycin-resistant gene under the control of the *Nanog* promoter ([Figure 4](#fig4){ref-type="fig"}C). We treated the cells with puromycin from day 7 to day 9 after OSKM introduction. Data also showed that both full-length *EphA7* and truncated *EphA7* were expressed to a much higher extent in NANOG-negative (puro^−^) cells than in NANOG-positive (puro^+^) cells ([Figure 4](#fig4){ref-type="fig"}D) and that the amount of secreted, truncated EPHA7 in the culture medium was greater in non-puromycin-added cell cultures than in puromycin-added ones ([Figure 4](#fig4){ref-type="fig"}E). These results suggest that EPHA7 expression was markedly decreased in fully reprogrammed cells.

We asked whether pre-reprogrammed cells expressing truncate EPHA7 are able to support other cells to progress toward a pluripotent state, and which kind of cells were affected by truncated EPHA7. We sorted OSKM-introduced *Nanog*-GFP MEFs into SSEA-1-positive and SSEA-1-negative cells at days 8 and 12. Sorted cells were then plated on the control shRNA-treated, OSKM-introduced wild-type (WT) MEFs or *EphA7* shRNA-treated, OSKM-introduced WT MEFs, and the number of *Nanog*-GFP colonies was examined. The results showed that the number of *Nanog*-GFP positive colonies was reduced when sorted cells were cultured on the *EphA7*-knockdown feeder cells at both days 8 and 12 ([Figures 4](#fig4){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}B). The extent of the reduction of *Nanog*-GFP positive colonies by *EphA7* knockdown in feeder cells was larger in SSEA-1-negative cells than in SSEA-1-positive cells at day 8. Next, SSEA-1-positive and SSEA-1-negative cells from OSKM-introduced *Nanog*-GFP MEFs were sorted at day 8 and plated on MEF feeder cells, and PBS or EPHA7^FC^ was added to the culture medium. We also prepared OCT3/4-overexpressing MEFs as feeder cells as OCT3/4 is responsible for the upregulation of truncated EphA7. The results showed that treatment with truncated EPHA7 or the use of OCT3/4-overexpressing feeder cells enhanced the generation of Nanog-positive colonies, especially from SSEA-1 negative cells ([Figure 4](#fig4){ref-type="fig"}G). Taken together, our results suggest that truncated EPHA7 is expressed and secreted from pre-reprogrammed cells and supports SSEA-1-negative cells to progress toward a pluripotent state.

Discussion {#sec3}
==========

Here, we have demonstrated that EPHA7 is upregulated during the early and middle periods of MEF reprogramming and that secreted, truncated EPHA7 promotes MEF reprogramming through inducing ERK1/2 activity reduction. EPH receptors and EPHRINs are critical regulators of cell-cell interactions and known to transmit bidirectional signaling. Moreover, several of EPH receptors and EPHRINs have their truncated forms, which are secreted to regulate EPH/EPHRIN signaling. Our results demonstrate that a truncated form of EPHA7, but not full-length EPHA7, plays a crucial role in reprogramming and that truncated EPHA7 is secreted to the culture medium to influence surrounding cells and promote their reprogramming.

Previous studies have demonstrated that the inhibition of ERK1/2 activity plays a role in acquiring and maintaining the naive pluripotent state of ESCs and iPS cells ([@bib20], [@bib26]). However, neither ERK1/2 activity changes during reprogramming nor their role in reprogramming has been addressed. Our data show that the reduction of ERK1/2 activity by truncated EPHA7 occurs in the middle phase (around day 6) of reprogramming and is essential for driving reprogramming.

Our results show that pre-reprogrammed cells mainly express and secrete truncated EPHA7 and that truncated EPHA7 has a stronger effect on SSEA-1-negative cells than on SSEA-1-positive cells. Notably, the reduction of the pERK/1/2 levels began at day 6 of reprogramming, SSEA-1-positive cells also started to emerge at day 6, and pERK1/2 levels remained higher in SSEA-1-negative cells than in SSEA-1-positive cells at day 6. Collectively, our results suggest that EPHA7-induced ERK activity reduction has a stronger effect on the middle phase of reprogramming and supports SSEA-1-negative cells to progress toward a pluripotent state.

The expression of truncated EPHA7 during reprogramming is transient, unlike most of the reprogramming-related genes that have high expression levels in mature ESCs or iPS cells. Microarray data in earlier reports ([@bib10], [@bib22], [@bib18]) also indicated that EPHA7 was mainly expressed in reprograming cells but not in ESCs or iPS cells. Moreover, our results show that the regulation of ERK1/2 activity by truncated EPHA7 is specific to cell reprogramming and may not be involved in pluripotency maintenance in ESCs and that the expression of eph receptors and ephrins is quite low in ESCs and iPS cells, indicating that EPH-EPHRIN signaling might not be involved in the regulation of the ERK1/2 pathway in ESCs.

Our analysis has demonstrated that the ERK activity reduction is not a result of the completion of reprogramming but is a crucial event during reprogramming, which drives reprogramming. This study identifies a secreted factor responsible for the ERK1/2 activity reduction during reprogramming. Thus, our findings reveal the importance of cell-cell communications during reprogramming.

Experimental Procedures {#sec4}
=======================

Cell Culture Protocols {#sec4.1}
----------------------

The MEFs for microarray, qRT-PCR analyses (experiments for [Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B) and establishment of iPS cells ([Figure S2](#mmc1){ref-type="supplementary-material"}F) were from E13.5 ICR mice. In other experiments, MEFs were derived by mating ICR mice and *Nanog*-GFP-IRES-PuroR mice (provided by RIKEN BRC through the national Bio-Resource Project of MEXT) ([@bib13]). The MEFs were maintained in DMEM)containing 10% fetal bovine serum (FBS). The Plat-E cells were maintained in DMEM containing 10% FBS, puromycin (1 μg/ml), and blasticidin S (10 μg/ml). HEK293T cells were maintained in DMEM containing 10% FBS and kanamycin (250 μg/ml). Cells undergoing reprogramming and ESCs (HT7) were cultured in a standard mouse ES medium containing 7.5% knockout serum replacement (Invitrogen), 7.5% HyClone standard FBS (Thermo) and 1,000 U/ml leukemia inhibitory factor (LIF) (Millipore). ESCs and mature iPS cells (iPS-MEF-Ng-20D-17; provided by the RIKEN BRC through the Project for Realization of Regenerative Medicine and the National Bio-Resource Project of MEXT) were cultured and passed on the mitomycin-C-treated MEF feeder cells in mouse ES medium with 1,500 U/ml LIF. All mouse experiments were conducted in accordance with the Regulation on Animal Experimentation at Kyoto University and approved by the Animal Experimentation Committee of Kyoto University.

Generation of Mouse iPS Cells {#sec4.2}
-----------------------------

In each gelatin-coated 35 mm dish, 1 × 10^5^ MEFs were seeded. The next day, cells were infected with the retroviruses in DMEM containing 10% FBS (day 0). Sixteen hours after infection, the medium was replaced with mouse ES medium. On day 2, the cells were plated onto new gelatin-coated 35 mm dishes, and ES medium was changed every 2 days. For the knockdown experiments, MEFs were infected with lentiviruses 2 days before infection with the retroviruses. For the rescue experiments, we added mouse recombinant EPHA7-Fc (EPHA7^FC^, R&D Systems, 608-A7-200) or PD0325901 (WAKO, 163-24001). EPHA7-Fc protein has the extracellular domain of mouse EPHA7 (Ala30-Pro549) and thus acts as truncated, secreted EPHA7.
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![EPHA7 Is Upregulated during MEF Reprogramming\
(A) qRT-PCR analysis of *EphA7* (full-length plus truncated *EphA7*) and truncated *EphA7*. Ctrl (control), *mCherry* instead of OSKM.\
(B) qRT-PCR analysis of *Nanog*, endogenous *Oct3/4*, and *E-cadherin*.\
(C) Immunoblotting analysis for EPHA7, NANOG, E-CADHERIN, and α-TUBULIN (as a loading control). Triangles indicate full-length EPHA7 (top) and truncated EPHA7 (bottom).\
(D) Immunoblotting analysis of conditioned media. A triangle indicates truncated EPHA7.\
(E) ELISA of the conditioned medium for EPHA7.\
(F) qRT-PCR analysis of *EphA7* and truncated *EphA7*. *mCherry* (Ctrl), *Oct3/4*, *Sox2*, *Klf4*, c-*Myc*, or OSKM was introduced to MEFs at day 0.\
(G) qRT-PCR analysis of both full-length *EphA7* and truncated *EphA7*. *Oct3/4* was introduced to MEFs at time 0. Ctrl, *mCherry*.\
(H) Potential OCT3/4 biding sites in the upstream region of *EphA7*.\
(I) Chromatin fragments of the OCT3/4 introduced MEFs were immunoprecipitated with control immunoglobulin G (IgG) or anti-OCT3/4 antibody. Each site was quantified by qRT-PCR. The values with control IgG were set to 1. Data are shown as mean ± SEM (sites B and D, n = 4 \[^∗^p \< 0.05\]; site E, n = 3; site A, n = 2 independent experiments; site C, not detected). The p values were calculated using Student's unpaired two-tailed t tests.\
In (A), (B), (F), and (G), data are shown as mean ± SEM (n = 3 independent experiments).](gr1){#fig1}

![Truncated EPHA7 (EPHA7^FC^), but Not Full-Length EPHA7, Enhances Reprogramming Efficiency\
(A) Knockdown efficiencies of *EphA7* shRNAs. *EphA7* mRNA levels at day 6 were determined. *Luciferase* shRNA (sh *Luc*), control.\
(B) Effect of *EphA7* shRNAs on *Nanog* mRNA levels during reprogramming.\
(C) Effect of *EphA7* shRNAs on the number of NANOG-positive colonies. Left: representative images at day 12 (left). Top: NANOG-positive colonies; bottom: Hoechst. The scale bars represent 2 mm. Right: quantification.\
(D) Effect of exogenous expression of full-length EPHA7 on reprogramming efficiency. Full-length *EphA7* or *mCherry* (Ctrl) was expressed in control shRNA-treated, OSKM-introduced MEFs (sh *Luc*) or in *EphA7* shRNA-treated, OSKM-introduced MEFs (sh *EphA7* \#1 and \#4). In (D), (E), and (G), quantification of the NANOG-positive colonies is shown.\
(E) Effect of the addition of truncated EPHA7 protein to the culture medium on reprogramming efficiency. EPHA7^FC^ (a truncated form of EPHA7; 5 μg/ml) was added to the culture medium at day 6 and incubated until day 10.\
(F) Effect of the exogenous expression of full-length *EphA7* or the addition of truncated EPHA7 protein to the culture medium on *Nanog* mRNA levels during reprogramming.\
(G) Effect of the addition of truncated EPHA7 protein (EPHA7^FC^) to the culture medium at the different time points.\
In (A)--(G), data are shown as mean ± SEM (n = 3 independent experiments; n = 4 independent experiments in \[C\]; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001). The p values were calculated using Student's unpaired two-tailed t tests.](gr2){#fig2}

![Truncated EPHA7 Promotes MEF Reprogramming through Inducing ERK Activity Reduction\
(A) Immunoblotting analysis for pERK1/2 in *mCherry* (Ctrl) or OSKM-introduced MEFs. The samples here were the same as those used in [Figure 1](#fig1){ref-type="fig"}C.\
(B) Immunoblotting analysis for pERK1/2 levels in *EphA7* shRNA-treated cells.\
(C) Effect of the addition of truncated EPHA7 on pERK1/2 levels. EPHA7^FC^ (5 μg/ml) was added to the culture medium in OSKM-introduced MEFs treated with *EphA7* shRNA \#4 or sh *Luc* at day 8.\
(D) *EphA7* shRNA (\#1)-treated, OSKM-introduced MEFs were treated with the MEK inhibitor PD0325901 (0.5 μM) for 2 days as indicated and examined for the number of Nanog-positive colonies at day 12. Left: representative images; right: quantification. The scale bars represent 1 mm.\
(E) Effect of the addition of truncated EPHA7 and/or the MEK inhibitor (PD0325901) treatment on reprogramming efficiency. EPHA7^FC^ was added to the culture medium from day 6 to day 10. PD0325901 treatment was from day 7 to day 8. The number of NANOG-positive colonies at day 12 was examined.\
In (D) and (E), data are shown as mean ± SEM (n = 3 independent experiments; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001). The p values were calculated using Student's unpaired two-tailed t tests.](gr3){#fig3}

![Truncated EPHA7 Is Expressed and Secreted from Pre-reprogramming Cells and Supports SSEA-1-Negative Cells to Progress toward a Pluripotent State\
(A) Immunoblotting analysis for pERK1/2 levels of the sorted samples (shown in [Figure S4](#mmc1){ref-type="supplementary-material"}A).\
(B) qRT-PCR analysis of truncated *EphA7* in the sorted samples.\
(C) A scheme for the puromycin selection experiment. OSKM were introduced into MEFs, derived from *Nanog*-GFP-IRES-PuroR mice, and the cells were treated with puromycin (1 μg/ml) from day 7 to day 9 for selection.\
(D) qRT-PCR analysis of *Nanog*, *EphA7* and truncated *EphA7* from cells treated with puromycin (NANOG^+^ cells) or without puromycin (NANOG^−^ cells/NANOG^+^ cells). In (B) and (D), data are shown as mean ± SEM (n = 3 independent experiments).\
(E) Immunoblotting analysis of conditioned media from cells treated with puromycin (NANOG^+^ cells) or without puromycin (NANOG^−^ cells/NANOG^+^ cells).\
(F) Effect of truncated EPHA7-expressing pre-reprogrammed cells on reprogramming of SSEA-1^+^ and SSEA-1^−^ cells. Left: a scheme for the experiment. OSKM-introduced *Nanog*-GFP MEFs were sorted into SSEA-1^+^ and SSEA-1^−^ cells at day 8 and plated on control shRNA-treated, OSKM-introduced WT MEFs (sh *Luc*) or on *EphA7* shRNA-treated, OSKM-introduced WT MEFs (sh *EphA7* \#1). Right: the number of NANOG-positive colonies after 4 days of incubation.\
(G) Effect of truncated EPHA7 on reprogramming of SSEA-1^+^ and SSEA-1^−^ cells. Left: a scheme for the experiments. OSKM-introduced *Nanog*-GFP MEFs were sorted into SSEA-1^+^ and SSEA-1^−^ cells at day 8 and plated on control WT MEFs or OCT3/4-overexpressing WT MEFs. EPHA7^FC^ (5 μg/ml) or PBS was added to the culture medium. Right: the number of NANOG-positive colonies after 4 days of incubation. In (F) and (G), data are shown as mean ± SEM (n = 3 independent experiments; ^∗^p \< 0.05). The p values were calculated using Student's unpaired two-tailed t tests.](gr4){#fig4}
